EUVIMEDEUVIMED entdecken
Multizentrische Studie

PEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients

Caroline Hochheuser iD, Maria L Rozeman, Nina Kunze, Nina U Gelineau, Carlijn Kuijk, Antoinette Jaspers-Bakker, Cor van den Bos, Miranda P Dierselhuis, Tirza J E Slager, Marta Fiocco, József Zsiros, Wim J E Tissing und 6 weitere

Stem Cells and Development · 2025

DOI: 10.1089/scd.2024.0178 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Stem Cells and Development, 2025. Verfasst von Caroline Hochheuser und 17 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Polyethylene Glycols, Heterocyclic Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous hematopoietic stem cell transplantation is used to restore bone marrow function after high-dose chemotherapy. For apheresis, granulocyte colony-stimulating factor (G-CSF) is standard of care, but obtaining sufficient stem cells can be challenging. Other mobilization agents include plerixafor and PEGylated G-CSF (PEG-G-CSF). While efficacy of these is established in adults, limited data for their use in pediatric patients are available. Here, we compare Good versus Poor Mobilizers and study success of different mobilization regimens in regard to CD34+cell-collection, -quality, -phenotype and hematologic reconstitution in pediatric patients. In this multi-center retrospective study, we analyzed data of 278 patients with solid tumors and lymphoma, mobilized with either G-CSF (n = 224), PEG-G-CSF (n = 34), or G-CSF/PEG-G-CSF with additional plerixafor (n = 20). In Poor Mobilizers (13.7% of all patients), addition of plerixafor to G-CSF augmented CD34+cell collection, without adverse effects on hematologic reconstitution and CD34+cell quality. PEG-G-CSF-aided mobilization was successful as first-line treatment in two-thirds of patients and did not impair hematological reconstitution, compared to G-CSF-only. Within the Poor Mobilizer group, G-CSF+plerixafor increased primitive (CD45RA-CD38-CD90+CD49f+) and CXCR4-expressing CD34+cells in apheresis products compared to G-CSF-only, without exceeding levels of Good Mobilizers. No plerixafor-related increase in tumor cells was observed in apheresis products. In conclusion, our comprehensive study supports the use of plerixafor and furthermore demonstrates the potential of patient-friendly PEG-G-CSF for mobilization of pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationPolyethylene GlycolsHeterocyclic CompoundsHematopoietic Stem Cell TransplantationHumansBenzylaminesCyclamsChildFemaleMaleAdolescentChild, PreschoolTransplantation, AutologousRetrospective StudiesAntigens, CD34InfantLymphomaRecombinant Proteins

Stichwörter der Autor:innen

PEGylated granulocyte colony-stimulating factorhematopoietic stem cell mobilizationhematopoietic stem cell transplantationpediatricsplerixaforpoor mobilizer

Substanzen

BenzylaminesCyclamsplerixaforGranulocyte Colony-Stimulating FactorPolyethylene GlycolsHeterocyclic CompoundsAntigens, CD34pegylated granulocyte colony-stimulating factorRecombinant Proteins

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Haematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Pediatric Oncology, Emma Children's Hospital (EKZ/AMC), Amsterdam, The Netherlands.
  • Department of Pediatric Oncology, University Medical Centre Groningen (UMCG), Groningen, The Netherlands.
  • Department of Clinical Pharmacy, Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Caroline Hochheuser, Ilse Timmerman

Zitieren

APA

Hochheuser, C., Rozeman, M. L., Kunze, N., Gelineau, N. U., Kuijk, C., Jaspers-Bakker, A., van den Bos, C., Dierselhuis, M. P., Slager, T. J. E., Fiocco, M., Zsiros, J., Tissing, W. J. E., Westinga, K., Zwaan, C. M., Voermans, C., Tytgat, G. A. M., Kraal, K. C. J. M., & Timmerman, I. (2025). PEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients. Stem Cells and Development. https://doi.org/10.1089/scd.2024.0178

Vancouver

Hochheuser C, Rozeman ML, Kunze N, Gelineau NU, Kuijk C, Jaspers-Bakker A, et al. PEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients. Stem Cells and Development. 2025. doi:10.1089/scd.2024.0178

BibTeX
@article{Hochheuser2025,
  author = {Hochheuser, Caroline and Rozeman, Maria L and Kunze, Nina and Gelineau, Nina U and Kuijk, Carlijn and Jaspers-Bakker, Antoinette and van den Bos, Cor and Dierselhuis, Miranda P and Slager, Tirza J E and Fiocco, Marta and Zsiros, József and Tissing, Wim J E and Westinga, Kasper and Zwaan, Christian M and Voermans, Carlijn and Tytgat, Godelieve A M and Kraal, Kathelijne C J M and Timmerman, Ilse},
  title = {PEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients},
  journal = {Stem Cells and Development},
  year = {2025},
  doi = {10.1089/scd.2024.0178}
}
Kostenlos starten →